Loading stock data…
KMDA
$8.21+0.07 (+0.86%)
Market ClosedLast close May 1
Kamada Ltd.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Kamada Ltd. in the Healthcare sector is trading at $8.21. The stock is currently 12% below its 52-week high of $9.35, remaining 10.8% above its 200-day moving average. Technical signals show neutral RSI of 42 and bearish MACD signal, explaining why KMDA maintains its current momentum and trend strength. The Whystock Score of 75/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 42) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$8.21
Potential Downside
27.8%
Whystock Fair Value$5.92
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$483.34M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
23.89
Beta
Defensive asset. Lower volatility than the S&P 500.
0.31
Div Yield
Strong income play. Yield provides a meaningful total return floor.
299.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-3.82%
Volume
Today's trading volume
75,878
Recent News
Midday Fly By: IEA to release 400M oil barrels, Oracle reports Q3 beat
The major averages were lower near noon, with the Dow dropping over 400 points as traders weigh shifting oil prices and a key inflation report. Markets are trading cautiously amid volatile energy prices and ongoing geopolitical tensions in the Middle East. Claim 70% Off TipRanks PremiumUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential Oil prices, which spiked
Kamada Ltd (KMDA) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Outlook
Kamada Ltd (KMDA) reports a 12% revenue increase and outlines future growth strategies amid market challenges.
Kamada Q4 Earnings Call Highlights
Kamada (NASDAQ:KMDA) executives told investors the company delivered “excellent” operational and financial performance in 2025 and entered 2026 with momentum across its commercial portfolio, while also addressing potential logistical concerns tied to the evolving situation in the Middle East. Opera
Kamada (KMDA) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
Although the revenue and EPS for Kamada (KMDA) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Kamada (KMDA) Q4 Earnings and Revenues Miss Estimates
Kamada (KMDA) delivered earnings and revenue surprises of -30.80% and -2.29%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?